How We Collaborate With Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations. We are committed to the goal of serving humankind through research into diseases and the development of new medicines and therapies.

Our Mission

Be a trusted partner for patient organisations and those they represent in the development of innovative medicines, education and services that improve patients' lives.

Aims of Our Collaboration

We are committed to working collaboratively with patient organisations that support the needs of patients, their families and/or caregivers. This offers an opportunity for us to learn from each other in order to:

  • Understand the needs and expectations patients, their families and their caregivers have, and the challenges they face in the current therapeutic and healthcare environments
  • Include the perspectives and needs of patients, their families and caregivers in the development of our medicines, clinical trials and patient support services
  • Increase patient satisfaction with our clinical trials and medicines
  • Increase disease awareness and improve patient education
  • Support patient access to medicines and healthcare services
  • Understand and support the objectives of patient organisations throughout the course of the patient’s disease

Our Guiding Principles

We believe true collaborations with patient organisations contribute to advances in research and healthcare innovation to serve patients, their families and caregivers by improving their health and quality of life.

These collaborations reflect Boehringer Ingelheim’s core values we believe in: Respect, Trust, Empathy and Passion, and are guided by the following principles:

  • We comply with any applicable laws, regulations and industry codes regulating the relationship between the pharmaceutical industry and patient organisations such as the EFPIA and FSA codices.
  • We work with patient organisations in an open, transparent and ethical manner.
  • We fully respect the views and independence of patient organisations, considering them as equal and valued partners with knowledge and experiences that Boehringer Ingelheim wishes to understand.
  • Collaborations between Boehringer Ingelheim and patient organisations are chosen on the basis of mutual goals with the aim to serve patient needs.
  • We engage with patient organisations and we are committed to establishing collaborations over the longer term.
  • We strive to provide information to patient organisations that is fully informed, accurate, easy-to-understand, and presented in a balanced way in order to help patient organisations achieve their goals.
  • We will engage with representatives of patient organisations who will serve as advisors, members of patient advisory boards, or speakers, for the purpose of supporting healthcare and research.
  • We will provide reasonable financial or non-financial support to patient organisations.
  • We encourage patient organisations to have a diverse range of funding sources and long-term strategy.
  • We encourage patient organisations to be transparent on their funding sources.
  • We do not request, expect, ask or encourage patient organisations to promote or support the usage of any specific product over another.
  • Any project collaboration with a patient organisation is based on a written agreement that clearly states the nature, purpose and duration of the activity, as well as any support (either financial or non-financial support) provided by Boehringer Ingelheim.
  • We report accurate, fair and objective information about our collaboration with patient organisations in a transparent manner.
  • We fully respect the privacy of personal data and do not expect patient organisations to provide any personal patient or family information.

Our Partners and Patient Advocacy Relations Function

Boehringer Ingelheim has been engaging with patient organisations over more than fifteen years through its global affiliates and its corporate organisation. In 2015 we created a global patient advocacy relations function to further coordinate our collaborations and activities with patient organisations.

During our project collaborations with patient organisations Boehringer Ingelheim’s Corporate Organisation (Boehringer Ingelheim GmbH) has provided financial and non-financial contributions to the following patient organisations:

Contributions
Payments to patient organisations 2023
Payments to patient organisations 2022
Payments to patient organisations 2021

 

Contacting Us

You can send us your query and feedback via email.

More Than Scleroderma
Scleroderma

More Than Scleroderma

A hub of knowledge, advice and support for those whose lives have been touched by scleroderma.
Read more